Werewolf Therapeutics(HOWL)2024-11-07 14:06Financial Performance - As of September 30, 2024, cash and cash equivalents were 135.3 million as of June 30, 2024, providing runway through at least the second quarter of 2026[4] - Collaboration revenue for Q3 2024 was 5.9 million in Q3 2023, as the company completed its obligations under the collaboration agreement with Jazz Pharmaceuticals[4] - The net loss for Q3 2024 was 8.3 million in Q3 2023[5] - The total operating expenses for Q3 2024 were 15.1 million in Q3 2023[8] - The weighted-average common shares outstanding increased to 43,704,836 in Q3 2024 from 35,653,924 in Q3 2023[8] Research and Development - Research and development expenses increased to 10.8 million in Q3 2023, primarily due to ongoing clinical trials for WTX-124 and WTX-330[5] - The company is actively enrolling patients in the Phase 1/1b clinical trial for WTX-124, with initial efficacy data expected in the first half of 2025[2] - WTX-330 demonstrated a 22-fold higher systemic prodrug exposure compared to recombinant IL-12 at its maximum tolerated dose, indicating improved therapeutic index[3] - The company plans to present interim data from the Phase 1 clinical trial of WTX-330 at the SITC Annual Meeting on November 9, 2024[3] - WTX-921, a new IL-10 INDUKINE candidate for inflammatory diseases, was added to the pipeline in October 2024, expanding the therapeutic focus beyond oncology[3] Contacts - Investor contact is John Norton from Precision AQ, reachable at 212.362.1200[10] - Media contact is Amanda Sellers from Deerfield Group, reachable at 301.332.5574[10] - Company contact is Ellen Lubman, Chief Business Officer of Werewolf Therapeutics[10]